165 related articles for article (PubMed ID: 34270868)
1. Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework.
Chan P; Marchand M; Yoshida K; Vadhavkar S; Wang N; Lin A; Wu B; Ballinger M; Sternheim N; Jin JY; Bruno R
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1171-1182. PubMed ID: 34270868
[TBL] [Abstract][Full Text] [Related]
2. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.
Claret L; Jin JY; Ferté C; Winter H; Girish S; Stroh M; He P; Ballinger M; Sandler A; Joshi A; Rittmeyer A; Gandara D; Soria JC; Bruno R
Clin Cancer Res; 2018 Jul; 24(14):3292-3298. PubMed ID: 29685883
[No Abstract] [Full Text] [Related]
3. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
Han K; Claret L; Sandler A; Das A; Jin J; Bruno R
BMC Cancer; 2016 Jul; 16():473. PubMed ID: 27412292
[TBL] [Abstract][Full Text] [Related]
4. External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data.
Kassir N; Chan P; Dang S; Bruno R
Cancer Chemother Pharmacol; 2023 Sep; 92(3):205-210. PubMed ID: 37410154
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer.
Gonçalves A; Marchand M; Chan P; Jin JY; Guedj J; Bruno R
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):68-78. PubMed ID: 37877248
[TBL] [Abstract][Full Text] [Related]
6. Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
Bruno R; Marchand M; Yoshida K; Chan P; Li H; Zou W; Mercier F; Chanu P; Wu B; Lee A; Li C; Jin JY; Maitland ML; Reck M; Socinski MA
Clin Cancer Res; 2023 Mar; 29(6):1047-1055. PubMed ID: 36595566
[TBL] [Abstract][Full Text] [Related]
7. Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.
Shemesh CS; Chan P; Marchand M; Gonçalves A; Vadhavkar S; Wu B; Li C; Jin JY; Hack SP; Bruno R
Clin Pharmacol Ther; 2023 Sep; 114(3):644-651. PubMed ID: 37212707
[TBL] [Abstract][Full Text] [Related]
8. Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study.
Yoshida K; Chan P; Marchand M; Zhang R; Wu B; Ballinger M; Sternheim N; Jin JY; Bruno R
AAPS J; 2022 Apr; 24(3):58. PubMed ID: 35484442
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer.
Ramagopalan S; Gupta A; Arora P; Thorlund K; Ray J; Subbiah V
JAMA Netw Open; 2021 Nov; 4(11):e2134299. PubMed ID: 34767024
[TBL] [Abstract][Full Text] [Related]
10. Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients.
Claret L; Mercier F; Houk BE; Milligan PA; Bruno R
Cancer Chemother Pharmacol; 2015 Sep; 76(3):567-73. PubMed ID: 26198314
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.
Hopkins AM; Kichenadasse G; Garrett-Mayer E; Karapetis CS; Rowland A; Sorich MJ
Clin Cancer Res; 2020 Jul; 26(13):3280-3286. PubMed ID: 32086341
[TBL] [Abstract][Full Text] [Related]
12. Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A.
Han K; Claret L; Piao Y; Hegde P; Joshi A; Powell JR; Jin J; Bruno R
CPT Pharmacometrics Syst Pharmacol; 2016 Jul; 5(7):352-8. PubMed ID: 27404946
[TBL] [Abstract][Full Text] [Related]
13. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.
Claret L; Gupta M; Han K; Joshi A; Sarapa N; He J; Powell B; Bruno R
J Clin Oncol; 2013 Jun; 31(17):2110-4. PubMed ID: 23650411
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
[TBL] [Abstract][Full Text] [Related]
17. Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors.
Hopkins AM; Kichenadasse G; McKinnon RA; Rowland A; Sorich MJ
Semin Oncol; 2019; 46(4-5):380-384. PubMed ID: 31735362
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
19. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
[TBL] [Abstract][Full Text] [Related]
20. Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study.
Claret L; Pentafragka C; Karovic S; Zhao B; Schwartz LH; Maitland ML; Bruno R
Cancer Chemother Pharmacol; 2018 Jul; 82(1):49-54. PubMed ID: 29700575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
